Control of Blood Glucose by Novel GLP-1 Delivery Using Biodegradable Triblock Copolymer of PLGA-PEG-PLGA in Type 2 Diabetic Rats
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Purpose. The incretin hormone glucagon-like peptide-1 (GLP-1) is a promising candidate for treatment of type 2 diabetes mellitus. However, plasma half-life of GLP-1 is extremely short, thus multiple injections or continuous infusion is required for therapeutic use of GLP-1. Therefore, we investigated a new delivery system as a feasible approach to achieve sustained GLP-1 release for a 2-week period.
Methods. A water-soluble, biodegradable triblock copolymer of poly [(dl-lactide-co-glycolide)-b-ethylene glycol-b-(-lactide-co-glycolide)] (ReGel) was used in this study as an injectable formulation for controlled release of GLP-1. GLP-1 was formulated into ReGel as insoluble zinc complex to stabilize GLP-1 against aggregation and slow down release. The GLP-1 release profile was monitored in vitro and in vivo. Zucker Diabetic Fatty rats were administered subcutaneously with the GLP-1 formulation. The concentration of GLP-1, insulin, and glucose was monitored every day after the GLP-1 administration.
Results. The GLP-1 release from ReGel formulation in vitro and in vivo showed no initial burst and constant release for 2 weeks. Animal study demonstrated that the plasma insulin level was increased, and the blood glucose level was controlled for 2 weeks by one injection of ReGel/ ZnGLP-1 formulation.
Conclusions. It is concluded that one injection of zinc-complexed GLP-1 loaded ReGel can be used for delivery of bioactive GLP-1 during a 2-week period. Because this new delivery system is biocompatible and requires twice-a-month injection, it can improve patient compliance and cost-effectiveness.
- R. M. Elliott, L. M. Morgan, J. A. Tredger, S. Deacon, J. Wright, and V. Marks. Glucagon-like peptide-1(7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns. Endocrinology 138:159–166 (1993).
- M. A. Nauck, N. Kleine, C. Orskov, J. J. Holst, B. Willms, and W. Creutzfeldt. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741–744 (1993).
- J. J. Holst, C. Orskov, O. V. Nielsen, and T. W. Schwartz. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211:169–174 (1987).
- D. M. Nathan. Insulinotropic action of glucagon-like peptide-1(7–37) in diabetic and nondiabetic subjects. Diabetes Care 15:270–276 (1992).
- J. Buteau. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphophatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42:856–864 (1999).
- W. Creutzfelt. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1(7–36)amide in type 1 diabetic patients. Diabetes Care 19:580–586 (1996).
- C. F. Deacon, A. H. Johnsen, and J. J. Host. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80:952–957 (1995).
- M. K. Gutniak, B. Linde, J. J. Holst, and S. Efendic. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039–1044 (1994).
- J. Larsen, B. Hylleberg, K. Ng, and P. Damsbo. Glucagon-like peptide-1 infusion must be maintained for 24 hours a day in order to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on treatment with sulphonylurea (SU failures). Diabetes Care 24:1416–1421 (2001).
- S. Cohen, T. Yoshioka, M. Lucarelli, L. H. Hwang, and R. Langer. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8:713–720 (1991).
- M. Malstom and B. Lindman. Self-assembly in aqueous block copolymer solutions. Macromolecules 25:5440–5445 (1992).
- B. Jeong, Y. H. Bae, D. S. Lee, and S. W. Kim. Biodegradable block copolymers as injectable drug-delivery systems. Nature 388:860–862 (1997).
- H. Gappa, M. Baudys, J. J. Koh, S. W. Kim, and Y. H. Bae. The effect of zinc-crystallized glucagon-like peptide-1 on insulin secretion of macroencapsulated pancreatic islets. Tissue Eng. 7:35–44 (2001).
- C. F. Deacon, M. A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms, and J. J. Host. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44:1126–1131 (1995).
- B. Ahren, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P. A. Jansson, M. Sandqvist, P. Bavenholm, S. Efendic, J. W. Eriksson, S. Dickinson, and D. Holmes. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869–875 (2002).
- CB. Juhl, M. Hollingdal, J. Sturis, G. Jakobsen, H. Agersø, J. Veldhuis, N. Porksen, O. Schmitz. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51:424–429 (2002).
- M. Zander, S. Madsbad, J. L. Madsen, and J. J. Holst. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824–830 (2002).
- C. M. Edwards, S. A. Stanley, R. Davis, A. E. Brynes, G. S. Frost, L. J. Seal, M. A. Ghatei, and S. R. Bloom. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am. J. Physiol. 281:E155-E161 (2001).
- J. J. Holst and C. F. Deacon. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663–1670 (1998).
- J. Rachman, F. M. Gribble, B. A. Barrow, J. C. Levy, and K. D. Buchanan, R.C. Turner, Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7–36) amide in patients with NIDDM. Diabetes 45:1524–1530 (1996).
- K. S. Polonsky, B. D. Given, L. J. Hirsch, H. Tillil, E. T. Shapiro, C. Beebe, B. H. Frank, J. A. Galloway, and E. van Cauter. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 318:1231–1239 (1988).
- R. E. Pratley and C. Weyer. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44:929–945 (2001).
- A. Mitrakou, D. Kelley, M. Mokan, T. Veneman, T. Pangburn, J. Reilly, and J. Gerich. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med. 326:22–29 (1992).
- Y. J. Kim and S. Choi. J. J. Koh, M. Lee, K. S. Ko, and S. W. Kim. Controlled Release of Insulin from Injectable Biodegradable Triblock Copolymer. Pharm. Res. 18:548–550 (2001).
- L. Pridal, H. Agerbaek, L. N. Christensen, K. Thomsen, and O. Kirk. Absorption of glucagons-like peptide-1 can be protracted by zinc or protamine. Int. J. Pharm. 136:53–59 (1996).
- Control of Blood Glucose by Novel GLP-1 Delivery Using Biodegradable Triblock Copolymer of PLGA-PEG-PLGA in Type 2 Diabetic Rats
Volume 21, Issue 5 , pp 827-831
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- glucagon-like peptide-1
- type 2 diabetes
- Industry Sectors